Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

Related Clinical Trial
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia Frontline Oral Arsenic Trioxide for APL A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia Total Marrow Irradiation for Refractory Acute Leukemia Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS) Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia PXD101 in Treating Patients With Acute Myeloid Leukemia Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Lymphocytic or Myelogenous Leukemia Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia Connect® MDS/AML Disease Registry Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia Vorinostat in Treating Patients With Acute Myeloid Leukemia Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AML Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia Red Cell Transfusion Goals in Patients With Acute Leukemias A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible A Safety Study of SGN-CD33A in AML Patients FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia ASCT for Relapsed APL After Molecular Remission Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup All-trans Retinoic Acid, and Arsenic +/- Idarubicin Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia AIDA 2000 Guidelines Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL French Registry of First-line Treatment of Acute Promyelocytic Leukemia New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia Proteasome Inhibition in Acute Promyelocytic Leukemia

Brief Title

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

Official Title

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

Brief Summary

      The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who
      are PCR-positive for the PML-RARα transcript and less than 18 years of age.
    

Detailed Description

      Acute promyelocytic leukemia (APL) in children has become a highly curable disease with the
      combination of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy with an
      overall remission rates equal to or higher than 98% and cure rates now exceeding 80% 1-9.

      Based on data coming from adults indicating that at least standard-risk APL patients may be
      cured without chemotherapy (i.e., with a treatment combining arsenic trioxide (ATO) and ATRA
      only) 10-12, this ICC APL 02 study was designed with the aim of validating the efficacy of a
      treatment combining:

        -  ATO and ATRA in newly diagnosed APL standard-risk (SR) children and adolescents and

        -  ATO, ATRA and gemtuzumab ozogamicin (GO) in newly diagnosed APL high-risk (HR) children
           and adolescents.

      Following one induction course of treatment combining ATO and ATRA +/- GO depending on risk
      stratification, patients will receive 4 ATO/ATRA based consolidation blocks. This is the
      first pediatric trial delivering a non-chemotherapy-based treatment for children with APL,
      being the whole treatment based on the use of ATRA, ATO (and GO in HR patients). The aim of
      the study is to demonstrate at least an equivalent efficacy and safety of this treatment not
      containing cytostatic agents compared to the standard protocols combining ATRA and
      chemotherapy (i.e. ICC APL Study 01).

      The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who
      are PCR-positive for the PML-RARα transcript and less than 18 years of age.

      This will be an international study, comprising the most important pediatric European groups,
      expecting to recruit 46 and 43 patients in SR and HR arms, respectively, in 3 years. The
      duration of study recruitment will be 36 months with a minimum follow-up per patient of 2
      years.

      The evaluation of morphological CR will be carried out after induction therapy, prior to the
      first block of consolidation therapy. MRD results after induction will not have an impact on
      subsequent therapy. By contrast, MRD results after the third consolidation course will
      influence the subsequent treatment, MRD-positive patients being eligible to rescue treatment,
      including hematopoietic stem cell transplantation (HSCT). BM aspirates will be repeated after
      the end of therapy, and 3 months, 6 months, 9 months and 12 months after treatment
      discontinuation.

      This is a collaborative international study in APL in children and adolescents aimed at
      providing information about procedures for the entry, treatment and follow-up of pediatric
      patients with APL. It is not intended that this document be used as an aide-memoir or guide
      for the treatment of other patients. Every care has been taken in its drafting, but
      corrections and amendments may be necessary. Before entering patients into the study,
      clinicians must ensure that the study has received clearance from their Local Research Ethics
      Committee and any other necessary body.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Event Free Survival (EFS) probability

Secondary Outcome

 Rate of hematological CR/CRi after induction

Condition

Acute Promyelocytic Leukemia

Intervention

Mylotarg

Study Arms / Comparison Groups

 Standard Risk (SR)
Description:  Patient with APL and WBC less than 10x10e9/L at presentation before start treatment

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

89

Start Date

October 9, 2019

Completion Date

October 10, 2024

Primary Completion Date

October 10, 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Newly diagnosed APL confirmed by the presence of PML/RARα fusion gene

          -  Age <18 years

          -  Written informed consent by parents or legal guardians

        Exclusion Criteria:

          -  Patients with a clinical diagnosis of APL but subsequently found to lack PML/RARα
             rearrangement should be withdrawn from the study and treated on an alternative
             protocol

          -  Significant liver dysfunction (bilirubin serum levels >3 mg/dL, ALT/AST serum levels
             greater than 5 times the normal values)

          -  Creatinine serum levels >2 times the normal value for age

          -  Significant arrhythmias, EKG abnormalities (*see below), other cardiac
             contraindications (L-FEV <50% or LV-FS <28%)

          -  Neuropathy

          -  Concurrent active malignancy

          -  Uncontrolled life-threatening infections

          -  Pregnant or lactating female

          -  Patients who had received alternative therapy (APL not initially suspected; ATRA
             and/or ATO not available
      

Gender

All

Ages

N/A - 18 Years

Accepts Healthy Volunteers

No

Contacts

Fanco Locatelli, Prof, 0039 051 2144667, [email protected]

Location Countries

Belgium

Location Countries

Belgium

Administrative Informations


NCT ID

NCT04793919

Organization ID

ICC APL STUDY 02

Secondary IDs

2017-002383-40

Responsible Party

Sponsor

Study Sponsor

Associazione Italiana Ematologia Oncologia Pediatrica


Study Sponsor

Fanco Locatelli, Prof, Principal Investigator, Dept. of Pediatric Hematology Oncology - Bambino Gesù Children's Hospital Rome


Verification Date

March 2021